Korro Bio (NASDAQ:KRRO) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Key Points

• Korro Bio reported a quarterly loss of $0.98 per share, beating analysts’ expected loss of $1.26 by $0.28.
• Shares fell $1.89 to $14.73 during Thursday’s midday trading, despite the earnings beat.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $16.50.

Korro Bio (NASDAQ:KRRO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.28, FiscalAI reports.

Korro Bio Stock Performance

KRRO stock traded down $1.89 during midday trading on Thursday, reaching $14.73. 436,190 shares of the company were exchanged, compared to its average volume of 195,677. Korro Bio has a 1-year low of $5.20 and a 1-year high of $36.79. The stock's 50-day simple moving average is $11.59 and its 200 day simple moving average is $12.02. The company has a market cap of $216.91 million, a price-to-earnings ratio of -1.47 and a beta of 3.23.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on KRRO shares. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Korro Bio in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Korro Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Jefferies Financial Group set a $15.00 price objective on shares of Korro Bio in a research report on Tuesday, October 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Korro Bio in a report on Friday, October 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Korro Bio presently has an average rating of "Moderate Buy" and a consensus target price of $16.50.

Insider Transactions at Korro Bio

In other news, SVP Oliver Dolan sold 7,347 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $13.51, for a total value of $99,257.97. Following the completion of the transaction, the senior vice president owned 16,252 shares in the company, valued at approximately $219,564.52. This represents a 31.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Lynx1 Capital Management Lp bought 25,124 shares of the company's stock in a transaction that occurred on Monday, October 26th. The stock was bought at an average cost of $11.75 per share, for a total transaction of $295,207.00. Following the completion of the transaction, the insider directly owned 1,624,789 shares in the company, valued at approximately $19,091,270.75. The trade was a 1.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 81,271 shares of company stock worth $904,203 and sold 38,269 shares worth $532,064. Insiders own 4.80% of the company's stock.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company's approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient's DNA.

Korro Bio's technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.